A comparison of two orally bioavailable anti-cancer agents, IRC-110160 and STX140

Anticancer Research

Volumn 28, Issue 3 A, 2008, Pages 1483-1491

  Foster, Paul A ^a   Stengel, C ^a   Ali, Tauhid ^b   Leese, Mathew P ^c   Potter, Barry V L ^c   Reed, Michael J ^a   Purohit, Atul ^a   Newman, Simon P ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b IPSEN   (France)

^c University of Bath   (United Kingdom)

Author keywords

2 methoxyestradiol; Breast cancer; ENMD 1198; Myelotoxicity; STX140

Indexed keywords

2 METHOXYESTRA 1,3,5(10),16 TETRAENE 3 CARBOXAMIDE; 2 METHOXYESTRADIOL 3,17 O,O BISSULFAMATE; CARBONATE DEHYDRATASE II; ESTRADIOL DERIVATIVE; GLYCOPROTEIN P; IRC 110160; STX 140;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD TOXICITY; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COCULTURE TECHNIQUES; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOTHELIAL CELLS; ESTRENES; FEMALE; FIBROBLASTS; HUMANS; MICE; NEOPLASMS, HORMONE-DEPENDENT; NEOVASCULARIZATION, PATHOLOGIC; TUBULIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 45949110337     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Ring AE and Ellis PA: Taxanes in the treatment of early breast cancer. Cancer Treat Rev 31: 618-627, 2005.
2. Fojo AT and Menefee M: Microtubule targeting agents: basic mechanisms of multidrug-resistance. Semin Oncol 32: S3-8, 2005.
3. Burkhart CA, Kavallaris M and Band Horwitz S: The role of beta-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta 1471: O1-9, 2001.
4. Lakhani NJ, Sarkar MA, Venitz J and Figg WD: 2-Methoxyoestradiol, a promising anticancer agent. Pharmacotherapy 23(2): 165-172, 2003.
5. Dingli D, Timm M, Russell SJ, Witzig TE and Rajkumar SV: Promising preclinical activity of 2-methoxyoestradiol in multiple myeloma. Clin Cancer Res 8(12): 3948-3954, 2002.
6. Pribluda VS, Gubish ER Jr, Lavallee TM, Treston A, Swartz GM and Green SJ: 2-Methoxyoestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev 19(1-2): 173-179, 2000.
7. Shang W, Konidari I and Schomberg DW: 2-Methoxyoestradiol, an endogenous oestradiol metabolite, differentially inhibits granulosa and endothelial cell mitosis: a potential follicular antiangiogenic regulator. Biol Reprod 65(2): 622-627, 2001.
8. Zhu BT and Conney AH: Is 2-methoxyoestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res 58(11): 2269-2277, 1998.
9. Fotsis T, Zhang Y, Pepper MS, Adlercreutz H, Montesano R, Nawroth PP and Schweigerer L: The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 368(6468): 237-239, 1994.
10. Klauber N, Parangi S, Flynn E, Hamel E and D'Amato RJ: Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyoestradiol and taxol. Cancer Res 57(1): 81-86, 1997.
11. Dahut WL, Lakhani NJ, Gulley JL, Arlen PM, Kohn EC, Kotz H, McNally D, Parr A, Nguyen D, Yang SX, Steinberg SM, Venitz J, Sparreboom A and Figg WD: Phase I clinical trial of oral of 2-methoxyoestradiol, an antiangiogiogenic and apoptotic agent, in patients with solid tumours. Cancer Biol Ther 5(1): 22-27, 2006.
12. Newman SP, Ireson CR, Tutill HJ, Day JM, Parsons MF, Leese MP, Potter BVL, Reed MJ and Purohit A: The role of 17β-hydroxysteroid dehydrogenases in modulating the activity of 2-methoxyoestradiol in breast cancer cells. Cancer Res 66(1): 324-330, 2006.
13. Sano T, Hirasawa G, Takeyama J, Darnel AD, Suzuki T, Moriya T, Kato K, Sekine H, Ohara S, Shimosegawa T, Nakamura J, Yoshihama M, Harada N and Sasano H: 17 beta-Hydroxysteroid dehydrogenase type 2 expression and enzyme activity in the human gastrointestinal tract. Clin Sci (Lond) 101(5): 485-491, 2001.
14. James J, Murry DJ, Treston AM, Storniolo AM, Sledge GW, Sidor C and Miller KD: Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. Invest New Drugs 25: 41-48, 2006.
15. Ireson CR, Chander SK, Purohit A, Perera S, Newman SP, Parish D, Leese MP, Smith AC, Potter BVL and Reed MJ: Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents. Br J Cancer 90(4): 932-937, 2004.
16. Leese MP, Leblond B, Newman SP, Purohit A, Reed MJ and Potter BVL: Anti-cancer activities of novel D-ring modified 2-substituted estrogen-3-O-sulfamates. J Steroid Biochem Mol Biol 94(1-3): 239-251, 2005.
17. Newman SP, Foster PA, Ho YT, Day JM, Raobaikady B, Kasprzyk PG, Leese MP, Potter BVL, Reed MJ and Purohit A: The therapeutic potential of a series of orally bioavailable antiangiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers. Br J Cancer 97(12): 1673-1682, 2007.
18. Foster PA, Ho YT, Newman SP, Kasprzyk PG, Leese MP, Potter BVL, Reed MJ and Purohit A: 2-MeOE2bisMATE and 2-EtE2bisMATE induce cell cycle arrest and apoptosis in breast cancer xenografts as shown by a novel ex vivo technique. Breast Cancer Res Treat. Epub ahead of print, 2007.
19. Chander SK, Foster PA, Leese MP, Newman SP, Potter BVL, Purohit A and Reed MJ: In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol. Br J Cancer 96: 1368-1376, 2007.
20. Newman SP, Leese MP, Purohit A, James DR, Rennie CE, Potter BVL and Reed MJ: Inhibition of in vitro angiogenesis by 2-methoxy- and 2-ethyl-estrogen sulfamates. Int J Cancer 109: 533-540, 2004.
21. Raobaikady B, Reed MJ, Leese MP, Potter BVL and Purohit A: Inhibition of MDA-MB-231 cell cycle progression and cell proliferation by C-2-substituted oestradiol mono- and bis-3-O-sulphamates. Int J Cancer 117: 150-159, 2005.
22. Leese MP, Leblond B, Smith A, Newman SP, Di Fiore A, De Simone G, Supuran CT, Purohit A, Reed MJ and Potter BVL: 2-Substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity. J Med Chem 49: 7683-7696, 2006.
23. Utsumi T, Leese MP, Chander SK, Gaukroger K, Purohit A, Newman SP, Potter BVL and Reed MJ: The effects of 2-methoxyoestrogen sulphamates on the in vitro and in vivo proliferation of breast cancer cells. J Steroid Biochem Mol Biol 94(1-3): 219-227, 2005.
24. Day JM, Newman SP, Comninos A, Solomon C, Purohit A, Leese MP, Potter BVL and Reed MJ: The effects of 2-substituted oestrogen sulphamates on the growth of prostate and ovarian cancer cells. J Steroid Biochem Mol Biol 84: 317-325, 2003.
25. Ho YT, Newman SP, Purohit A, Leese MP, Potter BVL and Reed MJ: The effects of 2-methoxy oestrogens and their sulphamoylated derivatives in conjunction with TNF-alpha on endothelial and fibroblast cell growth, morphology and apoptosis. J Steroid Biochem Mol Biol 86: 189-196, 2003.
26. Wood L, Leese MP, Mouzakiti A, Purohit A, Potter BVL, Reed MJ and Packham G: STX140 induces caspase-dependent apoptosis in CAL51 breast cancer cells and overcomes resistance to TRAIL via cooperative activation of caspases. Apoptosis 9(3): 323-332, 2004.
27. Purohit A, Williams GJ, Howarth NM, Potter BVL and Reed MJ: Inactivation of steroid sulfatase by an active site-directed inhibitor, estrone-3-O- sulfamate. Biochemistry 34(36): 11508-11514, 1995.
28. Armstrong JM, Myers DV, Verpoorte IA and Edsall JT: Purification and properties of human erthyrocyte carbonic anhydrases. J Biol Chem 241: 5137-5149, 1966.
29. Foster PA, Newman SP, Leese MP, Bernetiere S, Diolez C, Camara J, Hacher B, Baronnet M-M, Ali T, Potter BVL, Reed MJ and Puorhit A: A new micronized formulation of 2-methoxyestradiol-bis-sulfamate (STX140) is therapeutically potent against breast cancer. Anticancer Res, in press, 2008.
30. Elgqvist J, Bernhardt P, Hultborn R, Jensen H, Karlsson B, Lindegren S, Warnhammar E and Jacobsson L: Myelotoxicity and RBE of 211 At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice. J Nucl Med 46(3): 464-471, 2005.
31. Nemzek JA, Bolgos GL, Williams BA and Remick DG: Differences in normal values for murine white blood cell counts and other hematological parameters based on sampling site. Inflamm Res 50(10): 523-527, 2001.
32. Newman SP, Foster PA, Stengel C, Day JM, Ho YT, Judde J-G, Lassalle M, Prevost G, Leese MP, Potter BVL, Reed MJ and Purohit A: The orally bioavailable microtubule disruptor, STX140, is efficacious in vitro and in vivo in taxane resistant breast carcinoma cells. Clin Cancer Res 14(2): 597-606, 2008.
33. Ho YT, Purohit A, Vicker N, Newman SP, Robinson JJ, Leese MP, Ganeshapillai D, Woo LW, Potter BVL and Reed MJ: Inhibition of carbonic anhydrase II by steroidal and non-steroidal sulphamates. Biochem Biophys Res Commun 305(4): 909-914, 2003.
34. Purohit A, Hejaz HA, Walden L, MacCarthy-Morrogh L, Packham G, Potter BVL and Reed MJ: The effect of 2-methoxyoestrone-3-O-sulphamate on the growth of breast cancer cells and induced mammary tumours. Int J Cancer 85(4): 584-589, 2000.
35. Bubert C, Leese MP, Mahon MF, Ferrandis E, Regis-Lydi S, Kasprzyk PG, Newman SP, Ho YT, Purohit A, Reed MJ and Potter BV: 3,17-disubstituted 2-alkylestra-l,3,5(10)-trien-3-ol derivatives: synthesis, in vitro and in vivo anticancer activity. J Med Chem 50(18): 4431-4443, 2007.
36. Goss P, Stewart AK, Couture F, Klasa R, Glück S, Kaizer L, Burkes R, Charpentier D, Palmer M, Tye L and Dulude H: Combined results of two phase II studies of Taxol (paclitaxel) in patients with relapsed or refractory lymphomas. Leuk Lymphoma 34(3-4): 295-304, 1999.
37. Hanahan D, Bergers G and Bergsland E: Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumour angiogenesis in mice. J Clin Invest 105(8): 1045-1047, 2000.